Ignite Creation Date:
2025-12-24 @ 5:36 PM
Ignite Modification Date:
2025-12-27 @ 12:28 PM
Study NCT ID:
NCT04780568
Status:
RECRUITING
Last Update Posted:
2025-12-09
First Post:
2021-02-28
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer
Sponsor:
Ohio State University Comprehensive Cancer Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-01-18
Start Date Type:
ACTUAL
Primary Completion Date:
2026-07-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2029-07-31
Completion Date Type:
ESTIMATED
First Submit Date:
2021-02-28
First Submit QC Date:
None
Study First Post Date:
2021-03-03
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-02
Last Update Post Date:
2025-12-09
Last Update Post Date Type:
ESTIMATED